Simeon George
Signal active
Chief Executive Officer
Bio
Simeon joined SR One in 2007 and leads SR Ones investment activities on the West Coast. Prior to joining SR One, Simeon was a consultant at Bain & Company and an investment banker at Goldman Sachs and Merrill Lynch.
Simeon received his BA in Neuroscience from the Johns Hopkins University, where he graduated Phi Betta Kappa. Simeon received his MD from the University of Pennsylvania School of Medicine and his MBA (Mayer Scholar) from the Wharton School of the University of Pennsylvania.
Location
San Francisco, California, United States, North America
Social
Primary Organization
SR One
Founded
1985
Investment
190
Lead investment
60
Exits
58
Employees
1-10
Industry
Financial Services, Venture Capital, Finance, Health Care
Jobs history
4
Rezo Therapeutics
Board Member
Invalid date - Current
Board Member
Invalid date - Current
CRISPR Therapeutics
Board Member
Invalid date - Current
Design Therapeutics
Board Membe
2020 - Current
Board and Advisor Roles
0
N/A
Invest in regions
Profile Resume
Simeon George is the Chief Executive Officer at SR One, based in United States, North America. With a background in Financial Services, Simeon George has a rich history of leadership and innovation. Simeon George studied MD unknown @ University of Pennsylvania School of Medicine. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.
Recommendation from your interest
N/A
Investment portfolio
N/A
Number of investment
1
Number of exits
0
Personal investment
0
There is no personal investment available on this profile
Partner investment
17
| Annouced Date | Organization Name | Funding Round | Investor Name | Money Raised |
|---|---|---|---|---|
| Jan 27, 2022 | - | Series B - Simcha Therapeutics | SR One | 40.0M |
| Nov 17, 2022 | Rezo Therapeutics | Series A - Rezo Therapeutics | SR One | 78.0M |
| Jan 20, 2023 | ADARx Pharmaceuticals | Series B - ADARx Pharmaceuticals | SR One | 46.0M |
| Aug 09, 2023 | ADARx Pharmaceuticals | Series C - ADARx Pharmaceuticals | SR One | 200.0M |
SR OneExits
0
There is no exit available on this Profile
Invest in industries
Recent Activity
There is no recent news or activity for this profile.